The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) Recommends Approval for AbbVie's (ABBV) Shorter Regimen of Viekirax + Exviera in HCV-1b Infection

Source Link:

http://www.prnewswire.com/news-releases/abbvie-receives-chmp-positive-opinion-for-eight-week-treatment-option-with-viekirax-ombitasvirparitaprevirritonavir-tablets--exviera-dasabuvir-tablets-for-patients-with-genotype-1b-chronic-hepatitis-c-300413675.html